Reporting from ESMO 2019 Congress, Florian Lordick comments on results from the ATTRACTION-3 positive study with immune checkpoint inhibitor in second-line treatment for metastatic oesophageal squamous cancer that show clinically relevant benefit, although it is necessary to see if the results will translate also into non-Asian populations. He also discusses 2 presentations from the KEYNOTE-062 study with non-inferior health-related quality-of-life data and a biomarker analysis in first-line treatment for advanced gastric cancer - while no benefit was observed with immunotherapy alone in the overall study population, there was a clear benefit in patients with MSI-high tumours which justifies upfront testing and a specific treatment approach.
- LBA11: Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study
- LBA44: Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Patients With Advanced G/GEJ Cancer (GC) Including Outcomes According to Microsatellite Instability-High (MSI-H) Status in KEYNOTE-062
- LBA45: Health-Related Quality of Life (HRQoL) Impact of Pembrolizumab (P) Versus Chemotherapy (C) as First-Line (1L) Treatment in PD-L1–Positive Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma